-
Just 35% of heart attack survivors reported receiving outpatient cardiac rehabilitation services when surveyed by the Centers for Disease Control and Prevention.
-
-
The more scientists and public health officials learn about HIV prevention, the more they realize that targeting specific cultural and demographic groups of people who are not infected is a costly and labor-intensive venture.
-
The Caribbean receives scant attention from HIV researchers and public health officials, and this has resulted in an epidemic that is poorly understood, an investigator says.
-
Over-the-counter contraceptive products that contain the spermicide nonoxynol-9 (N-9) now will carry a warning label to alert consumers that such products do not protect against sexually transmitted diseases (STDs) and HIV/AIDS, following a final ruling by the Food and Drug Administration (FDA).
-
This multicenter, randomized, placebo-controlled trial of a synthetic GHRH analogue, tesamorelin (1-44 amino acids from the amino terminal of GHRH with a trans-3-hexenoyl group added to the amino terminal to increase the half-life over native GHRH), randomized 412 patients (86% male) to daily subcutaneous tesamorelin vs placebo for 26 weeks.
-
On Feb. 29, 2008, the FDA granted tentative approval for two generic formulations of drugs used to treat HIV/AIDS. These are stavudine capsules, 15 mg, 20 mg, 30 mg, and 40 mg., and efavirenz tablets, 600 mg, all manufactured by Hetero Drugs Limited, Hyberdad, India.
-
HIV-infected men who have sex with men (MSM) in resource-limited countries, often are overlooked, underserved, and discriminated against, international HIV/AIDS advocates say.
-
When international funds first became readily available for treating HIV-infected patients in resource-challenged economies, it was clear that many regions lacked trained clinicians for administering HIV antiretroviral treatment.
-